64 Result(s)

Article

Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin

Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dose-reduc...

M Bornhäuser, C Thiede, U Schuler, U Platzbecker… in Bone Marrow Transplantation (2000)

Article

Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin

A 17-year-old male with AML FAB M4 relapsed 4 months after myeloablative conditioning and peripheral blood stem cell transplantation (PBSCT) from an HLA-identical unrelated donor. A second PBSC harvest was inf...

U Platzbecker, K Klingel, C Thiede, J Freiberg-Richter… in Bone Marrow Transplantation (2001)

Article

Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia

Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified condi...

U Platzbecker, C Thiede, J Freiberg-Richter, C Röllig… in Bone Marrow Transplantation (2001)

Article

Double lumen port access in patients receiving allogeneic blood stem cell transplantation

We performed a prospective trial investigating the feasibility of a double lumen port access in 26 patients with hematological malignancies or solid tumors receiving either standard conditioning (n = 9, median ag...

U Platzbecker, T Illmer, M Schaich, J Freiberg-Richter… in Bone Marrow Transplantation (2001)

Article

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases

Within the past years, reduced or modified doses of chemotherapy or radiotherapy have been widely studied for conditioning before allogeneic hematopoietic cell transplantation in patients with myeloid leukemia...

U. Platzbecker, G. Ehninger, N. Schmitz, M. Bornhäuser in Annals of Hematology (2003)

Article

Expression of FLIP_Long and FLIP_Short in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis

Several apoptosis-inducing systems, including Fas/Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) and its receptors, are upregulated in myelodysplastic syndrome (MDS). FLIP (FLICE (FAS-associated ...

M Benesch, U Platzbecker, J Ward, H J Deeg, W Leisenring in Leukemia (2003)

Article

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Imatinib (Glivec^®, STI571) is an intracellular acting drug that demonstrates high activity against BCR-ABL-positive chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL). However, many patients...

T Illmer, M Schaich, U Platzbecker, J Freiberg-Richter, U Oelschlägel… in Leukemia (2004)

Article

Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission

A total of 22 patients with acute myeloid leukemia (AML) in first complete remission receiving autologous blood stem cell transplantation (ABSCT) were investigated in order to determine factors affecting outco...

D Strodtbeck, M Bornhäuser, M Hänel, L Lerche, M Schaich… in Bone Marrow Transplantation (2005)

Article

Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia

There is substantial need to improve the outcome of patients with high-risk acute myeloid leukemia (AML). The clinical trial reported here investigated a new approach of up-front allogeneic hematopoietic stem ...

U Platzbecker, C Thiede, M Füssel, G Geissler, T Illmer, B Mohr, M Hänel… in Leukemia (2006)

Article

Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells

R Wehner, M Wendisch, K Schäkel, M Bornhäuser, U Platzbecker, B Mohr, A Temme… in Leukemia (2006)

Article

Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34⁺ selected allogeneic hematopoietic cell transplantation

M Bornhauser, C Thiede, J Babatz, J Schetelig, T Illmer, A Kiani, U Platzbecker… in Leukemia (2006)

Article

Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multlineage dysplasia

U Platzbecker, U Germing, U Schäkel, T Illmer, S Soucek, M Schaich, G Ehninger… in Leukemia (2006)

Article

Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus

U Platzbecker, B Mohr, M von Bonin, M Binder, J Schetelig, G Ehninger… in Leukemia (2007)

Article

Induction of Toll-like receptor 2 and 4 expression on CD4⁺ and CD8⁺ T cells in G-CSF-mobilized unrelated peripheral blood stem cell grafts during leukapheresis: impact on patient outcome

U Platzbecker, J Stoehlmacher, C Pabst, E Goekkurt, U Oelschlägel… in Leukemia (2008)

Article

Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation

As low trough levels of mycophenolic acid (MPA) have been measured in recipients of allo-SCTs, we performed a pilot study targeting mycophenolate mofetil (MMF) doses according to the MPA area under the concent...

I Haentzschel, J Freiberg-Richter, U Platzbecker, A Kiani… in Bone Marrow Transplantation (2008)

Article

AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity

Neurotoxicity of cytarabine (AraC) is believed to be related to renal insufficiency. We examined the plasma pharmacokinetics of AraC and its deamination product uracil arabinoside (AraU) in four patients with ...

L. H. Lindner, H. Ostermann, W. Hiddemann, A. Kiani… in International Journal of Hematology (2008)

Article

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

Mesenchymal stem cells have been shown to mediate immunomodulatory effects. They have been used in patients with steroid-refractory acute GVHD (aGVHD), but their relevance as a therapeutic agent targeting aGVH...

M von Bonin, F Stölzel, A Goedecke, K Richter, N Wuschek… in Bone Marrow Transplantation (2009)

Article

Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine

M Wermke, C Thiede, A Kiani, G Ehninger, M Bornhäuser, U Platzbecker in Leukemia (2010)

Article

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

Patients with AML or myelodysplastic syndrome who relapse after allo-SCT have a poor prognosis. In the search for novel treatment strategies for these patients, we conducted a multicenter retrospective analysi...

A Czibere, I Bruns, N Kröger, U Platzbecker, J Lind… in Bone Marrow Transplantation (2010)

Article

Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy

S Tuve, J Gayoso, C Scheid, J Radke, A Kiani, D Serrano, U Platzbecker… in Leukemia (2011)